1. Home
  2. PBA vs UTHR Comparison

PBA vs UTHR Comparison

Compare PBA & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pembina Pipeline Corp. (Canada)

PBA

Pembina Pipeline Corp. (Canada)

HOLD

Current Price

$47.03

Market Cap

28.5B

Sector

Energy

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$545.59

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBA
UTHR
Founded
1997
1996
Country
Canada
United States
Employees
2974
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.5B
25.1B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
PBA
UTHR
Price
$47.03
$545.59
Analyst Decision
Hold
Buy
Analyst Count
1
14
Target Price
$60.00
$567.57
AVG Volume (30 Days)
1.4M
476.0K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
4.58%
N/A
EPS Growth
N/A
13.07
EPS
N/A
5.82
Revenue
N/A
$1,483,300,000.00
Revenue This Year
$3.45
$6.39
Revenue Next Year
$9.15
$14.18
P/E Ratio
$21.43
$93.33
Revenue Growth
N/A
2.38
52 Week Low
$35.45
$272.18
52 Week High
$50.10
$609.35

Technical Indicators

Market Signals
Indicator
PBA
UTHR
Relative Strength Index (RSI) 47.86 45.65
Support Level $46.44 $533.78
Resistance Level $49.83 $557.97
Average True Range (ATR) 0.96 12.32
MACD -0.20 0.48
Stochastic Oscillator 41.49 48.86

Price Performance

Historical Comparison
PBA
UTHR

About PBA Pembina Pipeline Corp. (Canada)

Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports. It also has a joint venture through the Cedar LNG export terminal.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: